Last reviewed · How we verify

NCT04526184

Systemic Effects of A Continuous Blood Flow Restricted Aerobic Exercise Session in COPD Patients: A Randomised Controlled Trial.

Status unknown NA Last updated 20 March 2024
What this trial tests

NA trial testing aerobic exercise with blood flow restriction in COPD in 46 participants. Status unknown.

Timeline
17 August 2020
Primary endpoint
19 March 2024
15 April 2024

Quick facts

Lead sponsorMedipol University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment46
Start date17 August 2020
Primary completion19 March 2024
Estimated completion15 April 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Medipol University

Who can join

Adults 40 to 75, male only, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with COPD that a pulmonologist classifies between Stage 1-2 in accordance with the GOLD criteria and age and gender-matched healthy individuals will be included in the study. In both groups (n = COPD: 17, Healthy: 17), aerobic exercise (AE) in the target heart rate range of 50% intensity, performed by cycling accompanied by blood flow restriction, will be applied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

Other Medipol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04526184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing